Phillip Gambel

Array ( [id] => 8476684 [patent_doc_number] => 20120276091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'Human Recombinant Monoclonal Antibody That Specifically Binds to VCAM-1 and Inhibits Adhesion and Transmigration Between Leukocytes and Endothelial Cells' [patent_app_type] => utility [patent_app_number] => 13/503103 [patent_app_country] => US [patent_app_date] => 2010-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 14702 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13503103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6125438 [patent_doc_number] => 20110086040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-14 [patent_title] => 'METHOD OF TREATING HEMOLYTIC DISEASE' [patent_app_type] => utility [patent_app_number] => 12/902617 [patent_app_country] => US [patent_app_date] => 2010-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 10195 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0086/20110086040.pdf [firstpage_image] =>[orig_patent_app_number] => 12902617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8417060 [patent_doc_number] => 20120244560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-27 [patent_title] => 'MONOCLONAL ANTIBODY AGAINST HUMAN HIG-1 POLYPEPTIDE' [patent_app_type] => utility [patent_app_number] => 13/498392 [patent_app_country] => US [patent_app_date] => 2010-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8552 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13498392 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7744846 [patent_doc_number] => 20120022236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-26 [patent_title] => 'Recombinant Anti-VLA4 Antibody Molecules' [patent_app_type] => utility [patent_app_number] => 12/891284 [patent_app_country] => US [patent_app_date] => 2010-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19774 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0022/20120022236.pdf [firstpage_image] =>[orig_patent_app_number] => 12891284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8300998 [patent_doc_number] => 20120183556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-19 [patent_title] => 'SUPPRESSANT FOR ATHEROSCLEROSIS' [patent_app_type] => utility [patent_app_number] => 13/498413 [patent_app_country] => US [patent_app_date] => 2010-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 5301 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13498413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7702630 [patent_doc_number] => 08088383 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-01-03 [patent_title] => 'Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies' [patent_app_type] => utility [patent_app_number] => 12/891415 [patent_app_country] => US [patent_app_date] => 2010-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 19101 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 229 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/088/08088383.pdf [firstpage_image] =>[orig_patent_app_number] => 12891415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6164849 [patent_doc_number] => 20110195063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-11 [patent_title] => 'Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor' [patent_app_type] => utility [patent_app_number] => 12/885406 [patent_app_country] => US [patent_app_date] => 2010-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 67046 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0195/20110195063.pdf [firstpage_image] =>[orig_patent_app_number] => 12885406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8846444 [patent_doc_number] => 08455627 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-04 [patent_title] => 'Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa' [patent_app_type] => utility [patent_app_number] => 12/877003 [patent_app_country] => US [patent_app_date] => 2010-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 50 [patent_no_of_words] => 10106 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 256 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12877003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6343516 [patent_doc_number] => 20100330096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-30 [patent_title] => 'METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 12/876800 [patent_app_country] => US [patent_app_date] => 2010-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5351 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0330/20100330096.pdf [firstpage_image] =>[orig_patent_app_number] => 12876800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4451388 [patent_doc_number] => 07964712 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-06-21 [patent_title] => 'Chimeric nucleic acids encoding polypeptides comprising TNF alpha, CD70 and FAS ligand domains' [patent_app_type] => utility [patent_app_number] => 12/871807 [patent_app_country] => US [patent_app_date] => 2010-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 9474 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/964/07964712.pdf [firstpage_image] =>[orig_patent_app_number] => 12871807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5975860 [patent_doc_number] => 20110070227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-24 [patent_title] => 'Treatment of Autoimmune and Inflammatory Diseases' [patent_app_type] => utility [patent_app_number] => 12/868338 [patent_app_country] => US [patent_app_date] => 2010-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 7963 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0070/20110070227.pdf [firstpage_image] =>[orig_patent_app_number] => 12868338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441477 [patent_doc_number] => 20120258093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY' [patent_app_type] => utility [patent_app_number] => 13/390236 [patent_app_country] => US [patent_app_date] => 2010-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13953 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13390236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8629402 [patent_doc_number] => 08361472 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-01-29 [patent_title] => 'Anti-PSGL-1 antibodies' [patent_app_type] => utility [patent_app_number] => 12/858110 [patent_app_country] => US [patent_app_date] => 2010-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8049 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12858110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8629401 [patent_doc_number] => 08361471 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-01-29 [patent_title] => 'Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody' [patent_app_type] => utility [patent_app_number] => 12/846232 [patent_app_country] => US [patent_app_date] => 2010-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 31 [patent_no_of_words] => 18688 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12846232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6201958 [patent_doc_number] => 20110064744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-17 [patent_title] => 'PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID' [patent_app_type] => utility [patent_app_number] => 12/836524 [patent_app_country] => US [patent_app_date] => 2010-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 22621 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20110064744.pdf [firstpage_image] =>[orig_patent_app_number] => 12836524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6095324 [patent_doc_number] => 20110002931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-06 [patent_title] => 'BISPECIFIC ANTIBODIES THAT BIND TO COMPLEMENT PROTEINS' [patent_app_type] => utility [patent_app_number] => 12/820654 [patent_app_country] => US [patent_app_date] => 2010-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 27503 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0002/20110002931.pdf [firstpage_image] =>[orig_patent_app_number] => 12820654 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6581808 [patent_doc_number] => 20100291109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-18 [patent_title] => 'TLR AGONIST (FLAGELLIN)/CD40 AGONIST/ANTIGEN PROTEIN AND DNA CONJUGATES AND USE THEREOF FOR INDUCING SYNERGISTIC ENHANCEMENT IN IMMUNITY' [patent_app_type] => utility [patent_app_number] => 12/797060 [patent_app_country] => US [patent_app_date] => 2010-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 16053 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20100291109.pdf [firstpage_image] =>[orig_patent_app_number] => 12797060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10121399 [patent_doc_number] => 09155745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-13 [patent_title] => 'Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs' [patent_app_type] => utility [patent_app_number] => 12/797166 [patent_app_country] => US [patent_app_date] => 2010-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 6802 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12797166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8041421 [patent_doc_number] => 20120070449 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-22 [patent_title] => 'METHODS OF TREATING INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 13/322455 [patent_app_country] => US [patent_app_date] => 2010-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 21970 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0070/20120070449.pdf [firstpage_image] =>[orig_patent_app_number] => 13322455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6134455 [patent_doc_number] => 20110008357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-13 [patent_title] => 'ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY' [patent_app_type] => utility [patent_app_number] => 12/786095 [patent_app_country] => US [patent_app_date] => 2010-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15188 [patent_no_of_claims] => 60 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0008/20110008357.pdf [firstpage_image] =>[orig_patent_app_number] => 12786095 [rel_patent_id] =>[rel_patent_doc_number] =>)